NCT02733029 - Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

May 30, 2022

Study Completion Date

February 1, 2023

Conditions

Renal Transplant Rejection

Interventions

DRUG

Sonazoid

Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles

DEVICE

contrast enhanced ultrasonography

Injection of intravenous ultrasound contrast

Trial Locations (1)

Brigham and Women's Hospital, Boston